摘要
垂体神经内分泌肿瘤是常见的颅内肿瘤,可产生过多的激素诱发全身疾病,或因肿瘤占位效应而引起头痛、眩晕或视力障碍。通过检测垂体神经内分泌肿瘤相关生物标志物有助于该病的早期发现、早期治疗,同时评估肿瘤的侵袭性对患者预后及治疗分析均具有重要临床意义。非编码RNA(non-coding RNA,ncRNA)是一种新兴的生物标志物,与垂体肿瘤的发生具有相关性,具有致癌或抑制肿瘤的特性,可在血清、血浆等生物液体中检测到,且具有创伤小、敏感性及特异性高等特点,有望成为垂体神经内分泌肿瘤的治疗及预后评估靶点。因此本文就ncRNA在垂体神经内分泌肿瘤中的研究进展进行综述。
Pituitary neuroendocrine tumor is a common intracranial tumor,which can produce excessive hor-mones to induce systemic disease,or cause headache,dizziness or visual impairment due to tumor mass effect.Diagnostic and prognostic biomarkers are conducive to early detection and surgical resection in early patients.Meanwhile,evaluation of tumor aggressiveness has important clinical significance for patient prognosis and treatment analysis.Non-coding RNA(ncRNA)is an emerging biomarker,which is associated with the occur-rence of pituitary tumors and has carcinogenic or tumor suppressive properties.NcRNA can be detected in se-rum,plasma and other biological fluids,and has the characteristics of low trauma,high sensitivity and specifici-ty.It is expected to provide a new therapeutic target and prognostic evaluation for pituitary neuroendocrine tu-mors.Therefore,this paper reviews the research progress of ncRNA in pituitary neuroendocrine tumors.
作者
徐辉
李楠
梁海乾
贾睿超
XU Hui;LI Nan;LI-ANG Hai-qian;JIA Rui-chao(Department of Neurosurgery,Characteristic Medical Center of Chinese People’s Armed Police Forces,Tianjin 300162,China)
出处
《神经损伤与功能重建》
2023年第6期356-359,共4页
Neural Injury and Functional Reconstruction
基金
国家自然科学基金项目(No.81871086)。
